Mark Gustavson
Senior Director & Head, Computational Pathology Strategic Partnerships AstraZeneca
Seminars
Wednesday 24th September 2025
Panel Discussion: H&E-Based Molecular Profiling: From Bench to Bedside in the Era of Precision Medicine & AI
12:10 pm
- AI-enabled H&E-based molecular profiling has the potential to transform the diagnosis and treatment pathway for cancer and beyond by overcoming key challenges of traditional wet lab methods – such as high cost, time-consuming processes, limited scalability, and variability in reproducibility – through rapid, scalable, and data-driven analysis
- The panel will discuss the enormous potential of utilising AI-enabled H&E-based molecular profiling in Clinics, Drug development and Drug discovery/Research
Wednesday 24th September 2025
Computational Pathology – Clearing the Way for More Robust IHC Biomarker Diagnostics
8:10 am
- Computational pathology is the next revolution in pathology enabling the development of more robust and accurate biomarker diagnostics
- QCS (Quantitative Continuous Scoring) was developed to quantify both target protein expression and spatial heterogeneity of target expression
- Discussing how AstraZeneca are leveraging QCS to quantify target expression to predict response of our oncology therapeutics, including Datopotamab deruxtecan (TROP2)
Wednesday 24th September 2025
Panel Discussion: Navigating the Common Pitfalls in Digital Pathology to Streamline CDx Development & Adoption
9:50 am
- What are the key strategies to overcome barriers to widespread adoption of digital pathology? And how can organizations build the necessary infrastructure to support digital pathology at scale?
- What are the commercial challenges facing digital pathology as a companion diagnostic and how can companies address these obstacles?
- What are the current regulatory challenges in getting digital pathology technologies approved for use as CDx, and how can these be addressed moving forward?
